logo

For the Inventor, By the Inventor

Zug, Switzerland

Crispr Therapeutics Ag


USPTO Granted Patents = 77



Trademarks = 9

Forward Citations = 174

Loading Chart...
Loading Chart...

72 inventors (with patents filed for the assignee):

goldMedal Demetrios Kalaitzidis (23 out of 23 patents)

silverMedal Jonathan Alexander Terrett (22 out of 36 patents)

bronzeMedal Alireza Rezania (20 out of 20 patents)

4.  Lawrence Klein (19 out of 25 patents)

5.  Rebeca Ramos-Zayas (15 out of 15 patents)

6.  Ante Sven Lundberg (9 out of 17 patents)

7.  Abraham Scaria (8 out of 28 patents)

8.  Akiko Noma (7 out of 7 patents)

9.  Roman Lvovitch Bogorad (6 out of 6 patents)

10.  Samarth Kulkarni (5 out of 9 patents)

11.  Hari Kumar Padmanabhan (5 out of 9 patents)

12.  Jason Gary Sagert (5 out of 48 patents)

13.  Ryo Takeuchi (5 out of 5 patents)

14.  Valentin Sluch (5 out of 5 patents)

15.  Mary-Lee Dequeant (5 out of 5 patents)


Core Competencies:
Universal Donor Cells
Gene-Edited Natural Killer Cells
Genetically Engineered T Cells
Optimized mRNA Encoding Cas9
RNA-Programmable Endonuclease Systems
Gene Editing for Hemophilia A
Immuno-Oncology
Chimeric Antigen Receptor
Stem Cell Differentiation
Cancer Treatment
Hereditary Diseases
Genome Editing

77 patents:

1. 12427170 - Universal donor cells (2025-09-30),
2. 12378572 - Universal donor cells (2025-08-05),
3. 12365915 - Universal donor cells (2025-07-22),
4. 12344656 - Genetically engineered T cells having improved persistence in culture (2025-07-01),
5. 12344655 - Gene-edited natural killer cells (2025-07-01),
6. 12304968 - T-cells expressing anti-LIV1 chimeric antigen receptor (2025-05-20),
7. 12263227 - Optimized mRNA encoding CAS9 for use in LNPs (2025-04-01),
8. 12247201 - Materials and methods for treatment of autosomal dominant retinitis pigmentosa (2025-03-11),
9. 12241087 - Compositions and methods for differentiating stem cells into NK cells (2025-03-04),
10. 12227763 - Methods and compositions for treating cancer (2025-02-18),
11. 12215320 - Compositions and methods for gene editing by targeting transferrin (2025-02-04),
12. 12215316 - Materials and methods for treatment of usher syndrome type 2A (2025-02-04),
13. 12203110 - RNA-programmable endonuclease systems and uses thereof (2025-01-21),
14. 12188060 - Messenger RNA encoding Cas9 for use in genome-editing systems (2025-01-07),
15. 12186406 - Materials and methods for treatment of hereditary haemochromatosis (2025-01-07),
CRISPR Therapeutics AG is a biopharmaceutical company focused on developing transformative gene-based medicines using its proprietary CRISPR/Cas9 gene-editing platform. The company's mission is to develop life-changing treatments for serious diseases by harnessing the potential of CRISPR/Cas9 to target and edit specific genes.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
77 Patents

#12 in Zug

#196 in Switzerland

#9,507 in the World

...
Zug, Switzerland

Crispr Therapeutics Ag

Forward Citations = 174

72 inventors:

goldMedal Demetrios Kalaitzidis (23 out of 23 patents)

silverMedal Jonathan Alexander Terrett (22 out of 36 patents)

bronzeMedal Alireza Rezania (20 out of 20 patents)

4.  Lawrence Klein (19 out of 25 patents)

5.  Rebeca Ramos-Zayas (15 out of 15 patents)

Please report any incorrect information to support@idiyas.com
Loading…